Glucosamine / Chondroitin Ramatiki ea Phallo ea Liteko tsa Teko

US le European Trial Results Se hlahisitsoeng bakeng sa Glucosamine

Sebokeng sa American College of Rheumatology Selemo sa Scientific Meeting (2005), ho ile ha hlahisoa liteko tse peli tsa glucosamine . Liphello tsa liteko tsena tse peli li ne li lebeletsoe haholo ke bafuputsi, lingaka le bakuli ba neng ba batla bopaki ba hore glucosamine e ne e le phekolo e nepahetseng bakeng sa ramatiki .

GAIT (Glucosamine / Chondroitin Arthritis Testing Invention) Phase I

Ho bakuli ba ka bang 1 600 ba nang le lefu la masapo le majoe a bohloko la knee ba fumanoe ho tloha liphuthehong tse 16 tsa thuto tsa rheumatology tsa US tsa thuto ea GAIT (GIT). Barupeluoa ba ithutile ba ile ba utloa bohloko bo boholo ba mangole 'me ba na le bopaki ba x-rase ea moriana oa masapo. Nakong ea thuto ea GAIT, bakuli:

Liphello tse Tsoang ho GAIT (Tlhaloso ea Thibelo ea Ramatiki ea Glucosamine / Chondroitin)

TATAISO (Glucosamine Unum In Die Efficiency)

Ho ne ho e-na le bakuli ba 318 thupelong ea tataiso le knee osteoarthritis (88% basali). Bakuli ba ne ba e-na le mefuta e mengata ea ho nka molomo oa glucosamine sulfate soluble phofo (1500 mg hang ka letsatsi), acetaminophen (1000 mg ka makhetlo a mararo ka letsatsi), kapa placebo ka likhoeli tse 6. Lihlopha tsohle li ile tsa lumelloa ho nka ibuprofen ha ho hlokahala.

Litholoana tse Tsoang ho Tataiso (Glucosamine Unum In Die Efficiency)

Phase II le Phase III GAIT Sephetho

Liphello tse tsoang karolong ea bobeli ea thuto ea GAIT li phatlalalitsoe koranteng ea Arthritis & Rheumatism ka 2008. Phase II e ile ea hlahlojoa motsoako oa glucosamine le chondroitin bakeng sa ho thibela tšenyo e kopaneng ea lengole. Ho kopana ha glucosamine le chondroitin ho ne ho bonahala eka ha ho na thuso ho thibela tšenyo e kopaneng e amanang le osteoarthritis ho feta placebo.

Barupeluoa ba ithutoang ba ileng ba lahleheloa ke sebaka se lekaneng sa sebaka se kopane ka lilemo tse peli ba ne ba le har'a lihlopha tse neng li nka glucosamine kapa chondroitin feela. Mohlomong, ho nka lintho tse peli tse tlatsetsang hammoho ho amana le ho kenngoa ha metsi, e leng ho ka 'nang ha hlahisa katleho e fokolang ea li-supplement ha li sebelisoa hammoho.

Phase III, e neng e nka lilemo tse 'nè tsa boitsebiso, e senoletse hore ho tlatsetsa ha motsoako kapa ka boeena ho ne ho se na molemo o moholo bakeng sa ho phomola ha lengole ho feta celecoxib kapa placebo. Liphetho li ile tsa hatisoa ka 2010 koranteng ea Annals of Rheumatic Disease .

Keletso ea Glucosamine

The Bottom Line

Ka 2012, The American College of Rheumatology e phatlalalitse litlhahiso tsa phekolo ea lefu la masapo a osteoarthritis. Ka tataiso, chondroitin kapa glucosamine e sa khothaletsoa bakeng sa phekolo ea pele ea lefu la osteoarthritis. Chondroitin le glucosamine e tlatsetsa feela kapa e kopantsoe e ka 'na ea se ke ea e-ba phekolo e nepahetseng bakeng sa bakuli bohle. E ka sebetsa ho bakuli ba itseng, mme haeba e sebetsa bakeng sa hau, tsoelapele kalafo - e nkoa e sireletsehile.

Lisebelisoa:

Phello ea glucosamine le / kapa chondroitin sulfate ho nts'etsopele ea lefu la masapo a mangole: tlaleho e tsoang tekong ea ho kenella ha masapo a glucosamine / chondroitin. Sawitzke et al. Ramatiki le Rheumatism. 2008 Oct; 58 (10): 3183-91.
http://www.ncbi.nlm.nih.gov/pubmed/18821708

Glucosamine / Chondroitin Ramatiki ea Tlhaloso ea Thibelo (GAIT). NIH. E fetotsoe ka January 2012.
https://nccih.nih.gov/research/results/gait

Tlhahlobo ea meriana le polokeho ea glucosamine, sulphate ea chondroitin, motsoako oa bona, celecoxib kapa placebo e nkiloeng ho phekola lefu la masapo a mabeli a lengole: liphello tsa lilemo tse 2 ho tsoa ho GAIT. June 2010. Annals ea mafu a Rheumatic. 2010; 69: 1459-1464
http://ard.bmj.com/content/69/8/1459.abstract?sid=fc95aeb7-1d79-4a79-9dac-c65916ca2125

Litlhahiso tsa Tšebeliso ea Mekhoa ea Boipheliso ea Meriana ea Boipheliso le ea Pharmacologic ea Osteoarthritis ea Hand, Hip le Knee.Kholejeng ea Amerika ea Rheumatology 2012. (Tlhokomelo ea Arthritis le Phuputso Vol. 64, No. 4, April 2012, maq. 465-474.)